Karikó has spent decades of her career exploring the therapeutic potential of mRNA, a component of DNA that is considered one of the key building blocks in life. Through many obstacles, job losses, doubt and movement across the ocean, Karikó stood by her conviction: mRNA could be used for something truly innovative. Now, that work is the basis of the Covid-19 vaccine.
Karikó, 65, began her career in native Hungary in the 1970s, when new mRNA research and opportunities looked endless. But the call of the American dream began (and more research and funding opportunities).
She continued her research at Temple, and then at the University of Pennsylvania School of Medicine. But by then, the flower was off the rose of an mRNA study, and Karikó’s idea that it could be used to fight disease was considered too radical, too financially risky to fund. She applied for grant after grant, but continued to receive a rejection, and in 1995, she was fired at UPenn. He was also diagnosed with cancer around the same time.
From doubt to bankruptcy
But she grabbed him.
That discovery is now the basis of the Covid-19 vaccine, and some have said that both Weissman and Karikó, who is now senior vice president of BioNTech, are based in the Germany, worthy of the Nobel Prize.
While recognition, after all this time, has to be nice, Karikó says it’s not scientific glory that’s on her mind right now.
“Truly, we celebrate when this human suffering is over, when this hardship and terrible time comes to an end, and hopefully in the summer when we forget about viruses and vaccines. And then I really celebrate, “she told CNN ‘s Chris Cuomo.
Karikó said she plans to get the vaccine soon, along with Weissman, and said she is “very, very confident” it will work. In fact, it was their findings that contributed to it.
Meanwhile, Karikó said she gave herself a little permission to celebrate the news of the vaccine: a bag of Goobers, her favorite candy.